source
- Alkermes' orexin agonist ALKS 7290 shows promise in early-stage ADHD trialAlkermes reported results from a Phase 1 study of its orexin agonist ALKS 7290, a drug class previously explored for rare sleep disorders. The trial enrolled adults with moderate to severe ADHD, a…
- Novo Nordisk outlines new obesity and consumer-focused strategy, targets five multi-blockbusters by 2030Novo Nordisk used its capital markets day to reassure investors by unveiling a plan to broaden its pipeline beyond diabetes and obesity. The company said it will aim to launch at least five multi-b…